NCT00623480已完成3 期
Randomized, Controlled, Parallel, Prospective Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects, as Applicable, Compared to That of Episodic Treatment
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 84
- 试验地点
- 38
- 主要终点
- Bleeding Frequency (Number of Total Bleeds)
研究概览
简要总结
To evaluate the effect of secondary prophylaxis as compared to episodic treatment on bleeding frequency (number of bleeds per year) and on joint damage.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 50 Years（Child, Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Males aged 12 to 50 years (US and Argentina)
- •Males aged 18 to 50 years (other countries)
- •Subjects with severe hemophilia A (<1% FVIII:C) as confirmed by the central lab from a sample obtained at least 96 hours after FVIII administration wash-out. Allow for the inclusion of a maximum of 10% (n=8) of patients with 1-2% FVIII:C baseline levels as long as they exhibit clinical severity and comply with all other inclusion criteria.
- •Subjects with at least 150 prior exposure days with any FVIII
- •Subjects who have been on episodic treatment and no known regular prophylaxis treatment for more than 12 consecutive months in the previous 5 years
- •Subjects with 6 to 24 bleeding events and/or treatments in the previous 6 months prior to study entry which are documented and available in the subjects medical records. Documentation can include records from previous physicians, specific home treatment records, emergency room or hospital records, x-ray reports, etc. The investigator can also document with a detailed note the number of bleeds reported by the subject in the last 6 months.
- •Subjects with inhibitor formation surveillance (inhibitor or recovery testing) over the ten years prior to enrollment documented by the investigator and who do not have a history of any of the following:
- •A positive inhibitor titer of 5.0 Bethesda Unit (BU) or greater by either BU assay system at any time since first exposure to exogenous factor VIII
- •A positive inhibitor test result of 1.0 or greater performed by the original BU assay at any time in the past 10 years (A subject can have more than one positive inhibitor test of 0.6 or greater by the original BU assay test but all must be less than 1.0 BU using the original BU assay.)
- •A positive inhibitor test result of 0.6 or greater performed by the Nijmegen method at any time in the past 10 years
- •Subjects with no inhibitor activity by Nijmegen-modified Bethesda assay, either positive (> 0.6 BU is considered positive) or borderline (> 0.3 and < 0.6 BU is considered borderline) as measured in the current study reference laboratory
排除标准
- •Subjects with any other bleeding disease besides hemophilia A (i.e. von Willebrand disease)
- •Subjects with thrombocytopenia (platelets < 100,000/mm3)
- •Subjects with abnormal renal function (Cockcroft-Gault Creatinine Clearance value of 60 mL/min or lower)
- •Subjects with active hepatic disease (Aspartate aminotransferase [AST] or Alanine aminotransferase [ALT] > 5xUpper Limit of Normal (ULN))
- •Subjects on treatment with immunomodulatory agents within the last 3 months prior to study entry or during the study (the following drugs are however allowed: interferon-a treatment for Hepatitis C virus (HCV), Highly active anti-retroviral therapy (HAART) therapy for human immunodeficiency virus (HIV) and/or a total of two courses of pulse treatment with steroids for a maximum of 7 days at 1mg/kg or less)
- •Subjects with an absolute CD4 lymphocyte cell count < 200 cells/mm3 (due to HIV, HCV or another suspected medical condition)
- •Subjects with known hypersensitivity to rFVIII, mouse or hamster proteins
- •Subjects who are receiving or had received other experimental drugs within 1 month prior to study entry
- •Subjects who require any pre-medication to tolerate FVIII injections (e.g. anti-histamines)
- •Subjects who are unwilling to comply with study visits or either of the possible treatment regimens
- •Subjects who have a planned orthopedic intervention to be performed during the study that may substantially affect bleeding (e.g. surgical or chemical or radiological synovectomy)
- •Subjects who are not suitable for participation in this study for any reason, according to the Investigator
- •Subjects who have poor joint status as defined by routine need for a wheelchair or unable to ambulate without the assistance of a brace, cane or crutches
- •Three or more joints that are already fused or "frozen" also called ankylosis
研究组 & 干预措施
Recombinant Factor VIII prophylaxis treatment
Experimental
Participants received 25 IU/kg of Recombinant Factor VIII (Kogenate FS, BAY14-2222) intravenously (IV), 3 times per week. Dose escalation steps by 5 IU/kg (to 30 IU/kg or 35 IU/kg maximum) for patients exhibiting a bleeding frequency of 12 bleeding episodes per year or greater.
干预措施: Recombinant Factor VIII (Kogenate FS, BAY14-2222) (Biological)
Recombinant Factor VIII on-demand treatment
Experimental
Participants received Recombinant Factor VIII (Kogenate FS, BAY14-2222) IV for bleeds in accordance with package insert instructions and study physician recommendations.
干预措施: Recombinant Factor VIII (Kogenate FS, BAY14-2222) (Biological)
结局指标
主要结局
Bleeding Frequency (Number of Total Bleeds)
时间窗: After the last enrolled patient has been in the study for 1 year. At the cut-off, the median follow-up duration was 616 days (minimum was 111 days and maximum was 1109 days)
次要结局
- Change From Baseline to 3 Years in the MRI (Magnetic Resonance Imaging) Scale.(Baseline and 3 years)
- Change From Baseline to 3 Years in the Colorado Adult Joint Assessment Scale(Baseline and 3 years)
研究者
研究点 (38)
Loading locations...
相似试验
已完成
4 期
Prophylaxis Versus on Demand Treatment for Children With Hemophilia AHemophilia ANCT01810666Bayer30
已完成
4 期
Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet TherapyHeart FailureNCT02836652Abbott Medical Devices72
已完成
2 期
Efficacy and Safety of PMK-S005 in the Prevention of Recurrent Peptic Ulcer in Low-dose Aspirin UsersPeptic UlcerNCT02342470PharmaKing88
终止
2 期
A Study to Evaluate the Safety of Apixaban in Acute Coronary Syndrome (ACS) Japanese PatientsAcute Coronary SyndromeNCT00852397Pfizer151
已完成
4 期
Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate CancerProstate CancerNCT01649635Sanofi45